Tak-Wah Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tak-Wah Wong has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
Chaw-Ning Lee
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University
6 shared publicationsJulia Yu-Yun Lee
Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan
5 shared publicationsShin-Chen Pan
Section of Plastic and Reconstructive Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4 shared publications- Chaw-Ning Lee
Department of Dermatology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan Taiwan
3 shared publications Chien-Chun Huang
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University
3 shared publications- Chun-Keung Yu
Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University; Insititute of Basic Medical Sciences, College of Medicine, National Cheng Kung University;
3 shared publications
Latest Publications
- 9 September 2026
- Published by Wolters Kluwer Health in Dermatologica Sinica
Successful treatment of arsenic-related multiple Bowen’s disease using daylight photodynamic therapy
Was not provided for this article.
- 9 September 2026
- Published by Wolters Kluwer Health in Dermatologica Sinica
Successful treatment of arsenic-related multiple Bowen’s disease using daylight photodynamic therapy
Was not provided for this article.
- 18 August 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (11) , 1660-1670
Impact of Lateral Margin Adequacy on Survival in Cutaneous Melanoma: An Asian Retrospective Cohort Study
The optimal surgical margin for cutaneous melanoma remains controversial, particularly in anatomically constrained areas such as the acral regions. We conducted a retrospective cohort study of 79 patients with invasive cutaneous melanoma treated at National Cheng Kung University Hospital between 2012 and 2024, including 51 cases of acral lentiginous melanoma (ALM). Patients were categorized as having adequate surgical margins (per NCCN guidelines) or inadequate but histologically tumor‐free margins. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), local recurrence‐free survival (LRFS), and melanoma‐specific survival (MSS), were analyzed using Kaplan–Meier estimates and Cox proportional hazards models after a median follow‐up of 60 months. No significant differences were observed in OS, LRFS, or MSS between the two groups. Although univariate analysis suggested a difference in PFS, the association did not persist in multivariate analysis, where margin inadequacy was not independently associated with poorer outcomes (OS: HR 1.81, 95% CI 0.84–3.90, p = 0.13; PFS: HR 1.87, 95% CI 0.90–3.87, p = 0.093). Subgroup analyses of ALM and high‐risk tumors (Breslow thickness > 2 mm) yielded consistent results, showing no significant differences in oncologic outcomes. In conclusion, our study showed that inadequate but histologically tumor‐free excision margins may not independently compromise survival outcomes in cutaneous melanoma. A narrower margin may be acceptable in selected patients when wider excision is precluded by anatomic or functional constraints.
- 18 August 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (11) , 1660-1670
Impact of Lateral Margin Adequacy on Survival in Cutaneous Melanoma: An Asian Retrospective Cohort Study
The optimal surgical margin for cutaneous melanoma remains controversial, particularly in anatomically constrained areas such as the acral regions. We conducted a retrospective cohort study of 79 patients with invasive cutaneous melanoma treated at National Cheng Kung University Hospital between 2012 and 2024, including 51 cases of acral lentiginous melanoma (ALM). Patients were categorized as having adequate surgical margins (per NCCN guidelines) or inadequate but histologically tumor‐free margins. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), local recurrence‐free survival (LRFS), and melanoma‐specific survival (MSS), were analyzed using Kaplan–Meier estimates and Cox proportional hazards models after a median follow‐up of 60 months. No significant differences were observed in OS, LRFS, or MSS between the two groups. Although univariate analysis suggested a difference in PFS, the association did not persist in multivariate analysis, where margin inadequacy was not independently associated with poorer outcomes (OS: HR 1.81, 95% CI 0.84–3.90, p = 0.13; PFS: HR 1.87, 95% CI 0.90–3.87, p = 0.093). Subgroup analyses of ALM and high‐risk tumors (Breslow thickness > 2 mm) yielded consistent results, showing no significant differences in oncologic outcomes. In conclusion, our study showed that inadequate but histologically tumor‐free excision margins may not independently compromise survival outcomes in cutaneous melanoma. A narrower margin may be acceptable in selected patients when wider excision is precluded by anatomic or functional constraints.
- 12 August 2026
- Published by Wolters Kluwer Health in Dermatologica Sinica
Cryosurgery and imiquimod provide long-term remission of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa
Was not provided for this article.
- 12 August 2026
- Published by Wolters Kluwer Health in Dermatologica Sinica
Cryosurgery and imiquimod provide long-term remission of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa
Was not provided for this article.
- Open Access
- 7 August 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (8) , e90137
Clinical Images: Bilateral eyelid swelling as the presenting feature of Sjögren's disease
- 7 August 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (8) , e90137
Open AccessClinical Images: Bilateral eyelid swelling as the presenting feature of Sjögren's disease
- Open Access
- 18 March 2025
- Published by Wolters Kluwer Health in Dermatologica Sinica
- Vol. 44 (1) , 86-87
Iontophoretic local anesthesia: A painless approach to hair transplantation in a patient with recessive dystrophic epidermolysis bullosa
- 18 March 2025
- Published by Wolters Kluwer Health in Dermatologica Sinica
- Vol. 44 (1) , 86-87
Open AccessIontophoretic local anesthesia: A painless approach to hair transplantation in a patient with recessive dystrophic epidermolysis bullosa
- Open Access
- 16 October 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 50, 104373
Topical indocyanine green antimicrobial photodynamic therapy for refractory feline chronic gingivostomatitis: A case report
- 16 October 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 50, 104373
Open AccessTopical indocyanine green antimicrobial photodynamic therapy for refractory feline chronic gingivostomatitis: A case report
- 19 September 2024
- Published by Elsevier in Applied Materials Today
- Vol. 41
An advanced ultrasound-activated drug delivery system with piezocatalytic MoS2 nanoflowers for treating patent ductus arteriosus
- 19 September 2024
- Published by Elsevier in Applied Materials Today
- Vol. 41
An advanced ultrasound-activated drug delivery system with piezocatalytic MoS2 nanoflowers for treating patent ductus arteriosus
- 29 March 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 205
Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
Facing a 40% mortality rate in candidemia patients, drug-resistant Candida and their petite mutants remain a major treatment challenge. Antimicrobial photodynamic therapy (aPDT) targets multiple fungal structures, unlike antibiotics/antifungals, potentially thwarting resistance. Traditional methods for inducing petite colonies rely on ethidium bromide or fluconazole, which can influence drug susceptibility and stress responses. This study investigated the application of green light (peak 520 nm) and rose bengal (RB) photosensitizer to combat a drug-resistant Candida glabrata isolate. The findings revealed that aPDT treatment significantly inhibited cell growth (≥99.9% reduction) and effectively induced petite colony formation, as evidenced by reduced size and loss of mitochondrial redox indicator staining. This study provides initial evidence that aPDT can induce petite colonies in a multidrug-resistant C. glabrata strain in vitro, offering a potentially transformative approach for combating resistant fungal infections.
- 29 March 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 205
Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
Facing a 40% mortality rate in candidemia patients, drug-resistant Candida and their petite mutants remain a major treatment challenge. Antimicrobial photodynamic therapy (aPDT) targets multiple fungal structures, unlike antibiotics/antifungals, potentially thwarting resistance. Traditional methods for inducing petite colonies rely on ethidium bromide or fluconazole, which can influence drug susceptibility and stress responses. This study investigated the application of green light (peak 520 nm) and rose bengal (RB) photosensitizer to combat a drug-resistant Candida glabrata isolate. The findings revealed that aPDT treatment significantly inhibited cell growth (≥99.9% reduction) and effectively induced petite colony formation, as evidenced by reduced size and loss of mitochondrial redox indicator staining. This study provides initial evidence that aPDT can induce petite colonies in a multidrug-resistant C. glabrata strain in vitro, offering a potentially transformative approach for combating resistant fungal infections.
- 11 March 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 254, 116202
A point-of-care electrochemical biosensor for the rapid and sensitive detection of biomarkers in murine models with LPS-induced sepsis
- 11 March 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 254, 116202
A point-of-care electrochemical biosensor for the rapid and sensitive detection of biomarkers in murine models with LPS-induced sepsis
- Open Access
Cordycepin Inhibits Enterovirus A71 Replication and Protects Host Cell from Virus-Induced Cytotoxicity through Adenosine Action Pathway
Enterovirus A71 (EV-A71) infection typically causes mild illnesses, such as hand-foot-and-mouth disease (HFMD), but occasionally leads to severe or fatal neurological complications in infants and young children. Currently, there is no specific antiviral treatment available for EV-A71 infection. Thus, the development of an effective anti-EV-A71 drug is required urgently. Cordycepin, a major bioactive compound found in Cordyceps fungus, has been reported to possess antiviral activity. However, its specific activity against EV-A71 is unknown. In this study, the potency and role of cordycepin treatment on EV-A71 infection were investigated. Results demonstrated that cordycepin treatment significantly reduced the viral load and viral ribonucleic acid (RNA) level in EV-A71-infected Vero cells. In addition, EV-A71-mediated cytotoxicity was significantly inhibited in the presence of cordycepin in a dose-dependent manner. The protective effect can also be extended to Caco-2 intestinal cells, as evidenced by the higher median tissue culture infectious dose (TCID50) values in the cordycepin-treated groups. Furthermore, cordycepin inhibited EV-A71 replication by acting on the adenosine pathway at the post-infection stage. Taken together, our findings reveal that cordycepin could be a potential antiviral candidate for the treatment of EV-A71 infection.
Open AccessCordycepin Inhibits Enterovirus A71 Replication and Protects Host Cell from Virus-Induced Cytotoxicity through Adenosine Action Pathway
Enterovirus A71 (EV-A71) infection typically causes mild illnesses, such as hand-foot-and-mouth disease (HFMD), but occasionally leads to severe or fatal neurological complications in infants and young children. Currently, there is no specific antiviral treatment available for EV-A71 infection. Thus, the development of an effective anti-EV-A71 drug is required urgently. Cordycepin, a major bioactive compound found in Cordyceps fungus, has been reported to possess antiviral activity. However, its specific activity against EV-A71 is unknown. In this study, the potency and role of cordycepin treatment on EV-A71 infection were investigated. Results demonstrated that cordycepin treatment significantly reduced the viral load and viral ribonucleic acid (RNA) level in EV-A71-infected Vero cells. In addition, EV-A71-mediated cytotoxicity was significantly inhibited in the presence of cordycepin in a dose-dependent manner. The protective effect can also be extended to Caco-2 intestinal cells, as evidenced by the higher median tissue culture infectious dose (TCID50) values in the cordycepin-treated groups. Furthermore, cordycepin inhibited EV-A71 replication by acting on the adenosine pathway at the post-infection stage. Taken together, our findings reveal that cordycepin could be a potential antiviral candidate for the treatment of EV-A71 infection.